Advance Search

EVALUASI PENGGUNAAN TERAPI ANTIBIOTIK EMPIRIS TERHADAP LUARAN KLINIS PASIEN PNEUMONIA KOMUNITAS RAWAT INAP

DOI: https://doi.org/10.20956/mff.v26i1.18888
Article History

Submited : November 25, 2021
Published : May 13, 2022

Keywords:
Pneumonia komunitas merupakan penyakit infeksi pada parenkim paru-paru yang mengancam jiwa sehingga dapat diberikan terapi antibiotik empiris. Penelitian ini bertujuan mengetahui nilai DDD dan kualitas penggunaan terapi antibiotik empiris menggunakan metode Gyssens pada pasien pneumonia komunitas rawat inap serta hubungannya terhadap luaran klinis pasien di RSUD Kota Makassar. Penelitian ini bersifat observasional dengan pengambilan data dilakukan secara retrospektif dari rekam medis pasien usia >19 tahun yang memenuhi kriteria inklusi periode Januari 2018-Desember 2019. Dikumpulkan data karakterisik pasien, pengobatan dan luaran klinis pasien setelah pemberian antibiotik. Analisis data dilakukan secara deskriptif dan dilanjutkan uji Chi square  untuk menganalisis hubungan penggunaan antibiotik dengan luaran klinis pasien. Karakteristik pasien yang beresiko yaitu usia, jenis kelamin, jumlah obat dan komorbid turut dianalisis. Hasil evaluasi kuantitatif antibiotik bahwa seftriakson memiliki DDD  tertinggi yaitu 44,9 DDD/100 patient-days, pada evaluasi kualitatif dari 74 sampel sebanyak 14 pasien (18,9%) memenuhi kategori ketepatan pemberian antibiotik (kategori 0) dan ketidaktepatan pemberian antibiotik pada kategori IVa sebanyak 50 pasien (67,6%), kategori IVb sebanyak 9 pasien (12,2%) dan kategori IIa sebanyak 1 pasien (1,4%). Uji chi-square menunjukkan tidak ada hubungan bermakna antara jumlah dan ketepatan penggunaan terapi antibiotik empiris terhadap luaran klinis pasien pneumonia komunitas pada periode Januari 2018-Desember 2019. Pasien yang memiliki komorbid baik yang berkategori infeksi maupun kategori infeksi dan non infeksi merupakan faktor resiko yang memiliki hubungan yang bermakna dengan luaran klinis pasien pada periode tersebut.

References

  1. Perhimpunan Dokter Paru Indoneisa. Pneumonia Komunitas : Pedoman Diagnosis & Penalataksanaan Di Indonesia. 2014. 5–52 p.
  2. 2. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet [Internet]. 2015;386(9998):1097–108. Available from: http://dx.doi.org/10.1016/S0140-6736(15)60733-4
  3. 3. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806–12. https://doi.org/10.1093/cid/cix647
  4. 4. Wunderink RG. Community-acquired pneumonia [Internet]. Fourth Edi. Vol. 1; 2017. 251-257.e1 p. https://doi.org/10.1016/B978-0-7020-6285-8.00028-99
  5. 5. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, Jose AS, Torres A. Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17(12).
  6. 6. Kementerian Kesehatan RI. Laporan Riskesdas 2018. Lap Nas Riskesdas 2018 [Internet]. 2018;53(9):154–65. Available from: http://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf
  7. 7. Brown JS. Community-acquired pneumonia. Clin Med J R Coll Physicians London. 2012;12(6):538–43. https://doi.org/10.7861/clinmedicine.12-6-538
  8. 8. Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37(4):1302–18. https://doi.org/10.1007/s12325-020-01248-7
  9. 9. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan RI Nomor 28 tahun 2021 tentang Pedoman Penggunaan Antibiotik. Jdih.Kemkes.Go.Id. 2021;1–97.
  10. 10. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):E45–67. https://doi.org/10.1164/rccm.201908-1581ST
  11. 11. Zaman S Bin, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A Review on Antibiotic Resistance: Alarm Bells are Ringing. Cureus. 2017;9(6). https://doi.org/10.7759/cureus.1403
  12. 12. World Health Organization. WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals. World Heal Organ [Internet]. 2018;1–102. Available from: https://www.who.int/medicines/access/antimicrobial_resistance/WHO-EMP-IAU-2018_01/en/
  13. 13. Kementrian Kesehatan Republik Indonesia. Pedoman Pelayanan Kefarmasian Untuk Terapi Antibiotika Kementrian Kesehatan Republik Indonesia. 2011;
  14. 14. WHO. WHO methodology for a global programme on surveillance of antimicrobial consumption. World Heal Organ https//http//www who int/medicines/areas/rational_use/WHO_AMCsurveillance_1 0 pdf. 2016;1–44.
  15. 15. Gyssens IC. Audits for monitoring the quality of antimicrobial prescriptions. Antibiot Policies Theory Pract. 2005;(Table 1):197–226. https://doi.org/10.1007/0-387-22852-7_12
  16. 16. Ambami S. Evaluasi Penggunaan Antibiotik dengan Metode ATC/DDD Pada Pasien Pneumonia di RSUD Jombang Periode Januari-Desember 2019. UIN Maulana Malik Ibrahim. 2020;(1):1–91.
  17. 17. Ilmi T, Restyana A, Kadir MBA, Yuniarto PF. Profile of Antibiotic Use and Germ Map in Pneumonia Patients in Pulmonary Space (Case Study at RSUD dr. Iskak. Tulungagung). J Phys Conf Ser. 2020;1569(3). https://doi.org/10.1088/1742-6596/1569/3/032064
  18. 18. Dorj G, Salvesen Blix H, Sunderland B, Gankhulug B, Tegshee O, Purevkhuu M, et al. Antibiotic Utilization Trends in Two State Hospitals of Mongolia from 2013 to 2017. Biomed Res Int. 2019;2019. https://doi.org/10.1155/2019/9160296
  19. 19. Bozkurt F, Kaya S, Tekin R, Gulsun S, Deveci O, Dayan S, et al. Analysis of antimicrobial consumption and cost in a teaching hospital. J Infect Public Health. 2014;7(2):161–9. https://doi.org/10.1016/j.jiph.2013.09.007.
  20. 20. Keita M, Traore F, Camara M, Camara A, Sandouno S, Hees T. The use of antibiotics in the university hospitals of Conakry: evaluation of the consumption and the analysis of determinants. Int J Community Med Public Heal. 2016;(January):1547–53.
  21. 21. Rawls SM. Antibiotics, β-Lactam. Encycl Neurol Sci. 2014;1:207–9. https://doi.org/10.1016/B978-0-12-385157-4.00250-5.
  22. 22. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(SUPPL. 2). https://doi.org/10.1086/511159
  23. 23. Scholar E. Ceftriaxone. xPharm: The Comprehensive Pharmacology Reference . 2007. https://doi.org/10.1016/B978-008055232-3.61412-6
  24. 24. Shirin M, Shahidul Islam M. Ceftriaxone, an Empirical Goldmine: A Systematic Review of Randomized Controlled Trials. Mathews J Pharm Sci. 2020;4(1):1–5. https://doi.org/10.30654/mjps.10001
  25. 25. Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YC, et al. Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J Antimicrob Chemother. 2011;66(6):1374–82. https://doi.org/10.1093/jac/dkr103
  26. 26. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect [Internet]. 2009;15(SUPPL. 3):12–5. Available from: http://dx.doi.org/10.1111/j.1469-0691.2009.02725.x
  27. 27. Joseph NM, Bhanupriya B, Shewade DG, Harish BN. Relationship between antimicrobial consumption and the incidence of antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae isolates. J Clin Diagnostic Res. 2015;9(2):DC08-DC12. https://doi.org/10.7860/JCDR/2015/11029.5537
  28. 28. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156(4 PART I):1040–8. https://doi.org/10.1164/ajrccm.156.4.9701046
  29. 29. Abel zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S. Cycling Empirical Antibiotic Therapy in Hospitals: Meta-Analysis and Models. PLoS Pathog. 2014;10(6). https://doi.org/10.1371/journal.ppat.1004225
  30. 30. Eljaaly K, Alshehri S, Aljabri A, Abraham I, Al Mohajer M, Kalil AC, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):1–7. https://doi.org/10.1186/s12879-017-2495-5
  31. 31. Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care. 2011;1(1):1–7. https://doi.org/10.1186/2110-5820-1-48
  32. 32. Gilman GA. Dasar Farmakologi Terapi, Edisi 10, Volume 3,. Terjemahan Tim Alih Bahasa Sekolah Farmasi ITB. 2012. Jakarta: Penerbit Buku Kedokteran EGC
  33. 33. Sandeep Nayar1, Ashfaq Hasan2, Pradyut Waghray3, Srinivasan Ramananthan4 JA, Jain5 R. Management of community‑acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies. Lung India. 2019;36(6):525–33. https://doi.org/DOI: 10.4103/lungindia.lungindia_38_19
  34. 34. Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther [Internet]. 2016;38(9):1930–47. Available from: http://dx.doi.org/10.1016/j.clinthera.2016.06.015
  35. 35. Jamal JA, Abdul-Aziz MH, Lipman J, Roberts JA. Defining antibiotic dosing in lung infections. Clin Pulm Med. 2013;20(3):121–8. https://doi.org/10.1097/CPM.0b013e31828fc646
  36. 36. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis. 2004;38(SUPPL. 4). https://doi.org/10.1086/382689
  37. 37. File TM. No Title [Internet]. Treatment of community-acquired pneumonia in adults in the outpatient setting. 2020. Available from: https://www.uptodate.com/contents/treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization?source=related_link
  38. 38. Zhang YQ, Zou SL, Zhao H, Zhang MM, Han CL. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. Am J Emerg Med [Internet]. 2018;36(10):1759–65. Available from: https://doi.org/10.1016/j.ajem.2018.01.079
  39. 39. Patil S, Mane R. Comparison of efficacy of levofloxacin-metronidazole combination versus ceftriaxone in cases of moderate diabetic foot infection. Int J Basic Clin Pharmacol. 2016;5(5):1775–9. https://doi.org/10.18203/2319-2003.ijbcp20163145
  40. 40. Stein GE, Goldstein EJC. Fluoroquinolones and anaerobes. Clin Infect Dis. 2006;42(11):1598–607. https://doi.org/10.1086/503907
  41. 41. Lexicomp. Levofloxacin (Systemic). Diakses 16/10/2020 jam 23.48 WITA
  42. 42. Noel GJ. A Review of Levofloxacin for the Treatment of Bacterial Infections. Clin Med Ther. 2009;1:CMT.S28. https://doi.org/10.4137/cmt.s28
  43. 43. Rivkin AM. Hepatocellular enzyme elevations in a patient receiving ceftriaxone. Am J Heal Pharm. 2005;62(19):2006–10. https://doi.org/10.2146/ajhp040452
  44. 44. Robles M, Toscano E, Cotta J, Isabel Lucena M, J. Andrade R. Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. Curr Drug Saf. 2010;5(3):212–22. https://doi.org/10.2174/157488610791698307.
  45. 45. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110. https://doi.org/10.2165/11539220-000000000-00000
  46. 46. Setiawan E, Widyati, Marpaung FR, Sukandar E, Susaniwati, Lukas DL, et al. Narrative Study on Pharmacokinetics of Antibiotics among Critically Ill Patients: the Implication on the Pharmacokinetics-Pharmacodynamics Target Attainment. Pharm Sci Res. 2019;6(1):1–12. https://doi.org/10.7454/psr.v6i1.4274
  47. 47. Munar MY, Singh H.Drug Dosing Adjustment in Patients with Chronic Kidney Disease. American Family Physician. 2007;75(10):1488–1496.
  48. 48. AHFS.LevoFLOXacin (Systemic) Monograph for Professionals - Drugs. com
  49. 49. Humaida R. Strategy to Handle Resistance of Antibiotics. Strateg To Handle Resist Antibiot J Major [Internet]. 2014;3(7):113–20. Available from: http://juke.kedokteran.unila.ac.id/index.php/majority/article/view/487%0Ahttp://juke.kedokteran.unila.ac.id/index.php/majority/article/view/487/488
  50. 50. Perhimpunan Dokter Paru Indonesia. Pneumonia komuniti 1973 - 2003. Pneumonia Komuniti (Pedoman diagnosis dan penatalaksanaan). 2003;6.
  51. 51. Rumende CM, Chen LK, Karuniawat A, Bratanata J, Falasiva R, Sitorus TP, et al. Hubungan Antara Ketepatan Pemberian Antibiotik Berdasarkan Alur Gyssens dengan Perbaikan Klinis Pasien pada Pneumonia Komunitas. J Penyakit Dalam Indones. 2019;6(2):71. https://doi.org/10.7454/jpdi.v6i2.335
  52. 52. Setiadi F. Analisis Faktor-Faktor Yang Mempengaruhi Outcome Terapi Pasien Pneumonia Di Rumah Sakit Umum Pusat Fatmawati Jakarta. 2019;5(3):18–28.
  53. 53. Peyrani P, Arnold FW, Bordon J, Furmanek S, Luna CM, Cavallazzi R, et al. Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course. Chest [Internet]. 2020;157(1):34–41. Available from: https://doi.org/10.1016/j.chest.2019.09.022
  54. 54. Tokgoz Akyil F, Yalcinsoy M, Hazar A, Cilli A, Celenk B, Kilic O, et al. Prognosis of hospitalized patients with community-acquired pneumonia. Rev Port Pneumol (English Ed [Internet]. 2018;24(3):164–9. Available from: http://dx.doi.org/10.1016/j.rppnen.2017.07.010
  55. 55. Nguyen MTN, Saito N, Wagatsuma Y. The effect of comorbidities for the prognosis of community-acquired pneumonia: An epidemiologic study using a hospital surveillance in Japan. BMC Res Notes [Internet]. 2019;12(1):1–5. Available from: https://doi.org/10.1186/s13104-019-4848-1
AB Pangeran, S., A. Manggau, M., & Djaharuddin, I. (2022). EVALUASI PENGGUNAAN TERAPI ANTIBIOTIK EMPIRIS TERHADAP LUARAN KLINIS PASIEN PNEUMONIA KOMUNITAS RAWAT INAP. Majalah Farmasi Dan Farmakologi, 26(1), 19-25. https://doi.org/10.20956/mff.v26i1.18888

Copyright (c) 2022 Array

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.
Fulltext
PDF